Latest News and Press Releases

LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...

LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...

LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...

LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...

--  Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE)...

- Prioritizing and expanding pulmonary disease programs based on early positive cystic fibrosis (CF) data for MRT5005, the first inhaled mRNA therapeutic –  - Discontinuing development of MRT5201, a...

-- Announced interim results from single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis (CF) -- -- Received FDA clearance to advance 2nd program into clinical development,...

-- MRT5005 was generally well tolerated at low and mid-dose levels; no serious adverse events reported at any dose level -- -- Marked increases in ppFEV1 (percent predicted forced expiratory volume...

LEXINGTON, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...

LEXINGTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...